Abstract 145P
Background
IO ± chemotherapy (CT) is first-line therapy for mNSCLC without actionable mutations. We aimed to identify a genomic signature potentially predicting resistance to IO using NGS.
Methods
Pts with mNSCLC who received IO or CT/IO were eligible. NGS was performed by TSO500HT® assay (DNA [522 genes], RNA [55 genes], Tumor Mutational Burden, Microsatellite Instability) or Oncomine Focus Assay® (DNA, 35 genes) plus Archer’s FusionPlex Lung Panel® (RNA, 17 genes), according to quality/quantity cellularity. A least absolute shrinkage and selection operator (LASSO) Cox regression was conducted to choose genes. The correlation between LASSO-selected genes and progression-free survival (PFS) was evaluated by univariable Cox regression. A risk score was derived using regression coefficients of significant genes in the multivariable analysis. Pts were divided into two groups based on the median risk score (0 vs >0). The risk score was evaluated in a multivariable model including clinical features.
Results
56 pts were retrospectively included. 32 (57%) received CT/IO and 23 (43%) IO. Median follow-up was 10.4 months. Among 346 genes, 15 resulted potentially predictive of PFS. At univariable analysis, 6 genes were significantly correlated to PFS: AKT3 (HR 40.39, 95% IC 5.58-292.30, p<0.001), ARID5B (HR 4.98, 95% IC 1.11-22.24, p=0.04), CD276 (HR 14.33, 95% IC 2.60-78.99, p=0.002), PAX8 (HR 8.33, 95% IC 1.78-38.95, p=0.007), PDGFRB (HR 4.88, 95% IC 1.42-16.75, p=0.01) and RICTOR (HR 3.82, 95% IC 1.08-13.57, p=0.04). In the multivariable analysis PAX8 was excluded and a genomic signature with 5 genes was considered. PFS was significantly different in the two risk groups: HR 13.56, 95% IC 5.30-34.67, p<0.001, with a median PFS of 1.64 (95% IC 0.76-NA) vs 13.25 months. (95% IC 10.88-NA). The genomic signature remained prognostic in a multivariable model including age, smoke, histology and regimen (HR 15.71; 95% IC 5.19-47.52, p<0.001).
Conclusions
A genomic signature including AKT3, ARID5B, CD276, PDGFRB and RICTOR alterations was significantly associated with shorter PFS in pts receiving IO. Validation in external cohort is ongoing.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Medical Oncology Unit, Fondazione Policlinico Agosto Gemelli.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
83P - Evaluation of serum macrophage inhibitory cytokine 1 as a diagnostic biomarker for pancreatic cancer: A systematic review and diagnostic accuracy meta-analysis
Presenter: Muhammed Elfaituri
Session: Cocktail & Poster Display session
Resources:
Abstract
84P - Profiling of lipid-loaded macrophages in melanoma
Presenter: Marta Pandini
Session: Cocktail & Poster Display session
Resources:
Abstract
85P - Whole-genome CRISPR screening identifies chemosensor receptors as key regulators of the cancer-macrophage crosstalk
Presenter: Giulia Marelli
Session: Cocktail & Poster Display session
Resources:
Abstract
86P - Regulation of cancer progression through the gut microbiome and immuno-nutrition
Presenter: Anikka Swaby
Session: Cocktail & Poster Display session
Resources:
Abstract
87P - Macrophage ontogeny underlies functional programs and drives brain tumor progression
Presenter: Miranda Yu
Session: Cocktail & Poster Display session
Resources:
Abstract
88P - Evaluating the infiltration of anti-NKG2DL CAR-T cells into a 3D cell culture developed in a Vitvo cartridge bioreactor
Presenter: Aigul Valiullina
Session: Cocktail & Poster Display session
Resources:
Abstract
89P - Immune homeostasis mediators and disease progression in chemotherapy-naïve and neoadjuvant chemotherapy treated gastric cancer patients
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
90P - Neutrophils as producers of endothelial growth factor in the progression of kidney cancer
Presenter: Ilseya Myagdieva
Session: Cocktail & Poster Display session
Resources:
Abstract
91P - The impact of the immunological context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: A systematic review
Presenter: Omar Mubarak
Session: Cocktail & Poster Display session
Resources:
Abstract
92P - Reduction in the relative lymphocyte count as a predictive biomarker for serious immune-related adverse events in patients with metastatic non-small cell lung cancer on immunotherapy: Single institution experience
Presenter: Antoan Garev
Session: Cocktail & Poster Display session
Resources:
Abstract